

Advancing Research. Improving Lives.™

NRG-CC012CD "SYMON"

Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

October 17, 2024 Practice Personnel Update

Presenters: Jamillah Gross-Caldwell, Grey Freylersythe

This NRG-Oncology protocol is being conducted in collaboration with NIH/NCI R01 #1R01CA279472-01 funding to Drs. Sikorskii MPI (contact), Badger (MPI) and Crane (MPI).



NRGOnc





Study Team

Principal Investigator Alla Sikorskii, PhD Michigan State University	Co-Chair, Health Disparities Terry Badger, PhD, RN, PMHCNS-BC, FAPOS, FAAN University of Arizona	Co-Chair, Patient Reported Outcomes Tracy Crane, PhD, RDN University of Miami
Co-Chair, Nursing Melyssa Foust, MSN, RN Upstate Carolina NCORP	NCORP Community Co- Chair Vamsi Krishna Vasireddy, DO Carle Cancer Institute	Statistician Stephanie Pugh, PhD NRG Oncology
<u>SWOG Champion</u> Virginia Sun, PhD, RN City of Hope	Alliance Champion Kelly A. Hirko, PhD, MPH Michigan State University	



See protocol for complete contact details





Contacts

Data Management For questions concerning eligibility or data submission	Lisa Abate abatel@nrgoncology.org Aaron Johnson johnsona@nrgoncology.org
Protocol Development For questions concerning protocol and informed consent versions & amendments	Erica Field, MPH, MHA fielde@nrgoncology.org
Project Managers For questions concerning patient recruitment, data collection, and intervention delivery.	Jamillah Gross-Caldwell, MSU 517-884-7662 Grey Freylersythe, UMiami 305-243-9832 Shared Inbox: symon@miami.edu







Advancing Research. Improving Lives.™

Brief Study Overview



Study Background

- There are currently more than 50 U.S. Food and Drug Administration (FDA)-approved oral anticancer agents, and their use is increasing
- Patients on oral agents must self-manage their symptoms (e.g., fatigue, anxiety, skin rash) with less interactions with on oncology team compared to infusion treatment
- Telemonitoring and management of symptoms are key for reducing symptom burden, emergency department or urgent care visits, hospitalizations, and treatment interruptions







Study Rationale

• Testing the implementation of the following conditions in real world of community-based oncology practices:

ATSM + TIPC (Automated Telephone Symptom Monitoring & <u>Handbook</u> +/-Telephone Interpersonal Counseling)

IVR Control (Telephone Symptom Monitoring only)

• Data will inform future implementation of this telehealth symptom monitoring strategy, including acceptability, appropriateness, cost, and cost savings due to reductions in unscheduled health service use.



Symptom Monitoring (both arms)

- 24 symptoms will be assessed via IVR weekly for <u>17 weeks</u> using Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- Symptom severity is rated as 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe
- Weekly summary for each patient is sent to practice (any person or people identified by practice)
- Practice personnel are not required to do anything specific based on the report, but report recipient(s) will be asked monthly what was done






Symptom Management (ATSM+TIPC arm only)

- Patients will be directed to a symptom management handbook in weeks 1-12, to contact their healthcare provider and/or to contact emergency services depending on their symptoms.
- Patients reported elevating psychosocial symptoms in weeks 1-4 will be referred to TIPC (telephone interpersonal counseling) for 8 weeks.





Participant Intervention







Advancing Research. Improving Lives.™


Study Updates





ONCOLOGY™

Progress



Site Characteristics






Approved Sites





- Opened to patient accrual officially 10/14/2024
 - 4 patients enrolled in 3 days!
- 7 sites with enrolled practice personnel
 - 20 total enrolled personnel







Review of Practice Study Activities





Practice Personnel Eligibility Criteria

Practice personnel will be key stakeholders in this research study, themselves consenting to participation, receiving reports, and completing brief monthly questionnaires. The practice personnel must provide study-specific informed consent prior to study entry.

Eligible: physicians, nurses, nurse practitioners, advanced practice providers, physician assistants, medical assistants, pharmacists and are involved in symptom management of patients on trial.

- Planned to be involved in usual care for at least one enrolled patient during patient's participation in the study.
- At least one practice personnel has to receive IVR reports and complete monthly forms (about 30 minutes)

If applicable – if site has behavioral health professional who will deliver TIPC intervention, they must have licensure or eligibility for licensure in behavioral counseling if required by the State or Territory.

Can be as few as **one** - person or as many as applicable, ideally ~4

Patient Key Eligibility Criteria

- Must be starting a new course of an oral anti-cancer agent (the list of agents is always posted to the CTSU website), within 4 weeks of registration.
 - Can be receiving sex hormone inhibitor in *conjunction* with other oral anti-cancer agent
 - **Cannot** be receiving treatment with immune checkpoint inhibitor at enrollment
 - All concomitant medications and supportive care treatments are acceptable.
- Cannot be receiving competing supportive care treatments:
 - Cannot be in any other symptom monitoring/management programs or studies
 - Cannot have had 2+ counseling/therapy sessions in past month for mood/psychosocial wellbeing
- Cannot be in hospice at time of enrollment
- Must be able to speak and understand English or Spanish.
- Must have access to a telephone with a touchpad and ability to hear a recording





Patient Enrollment

Plan to enroll 2 patients per month on average Process:







Key Recruitment Notes

- Patients will participate for 17 weeks
- Patients will:
 - Receive 3 phone calls for interviews by study staff (baseline, week 13, and week 17)
 - Receive weekly *automated* phone calls for all 17 weeks to report their symptoms using their keypad
- Some patients may also receive TIPC with a behavioral health specialist for 8 weeks if:

1) they are enrolled by an ATSM+IVR site and

2) they report elevated emotional distress for two consecutive weeks in the first 4 weeks of the study

Calls will be coming from: 888-602-8325 (Caller ID: MWR UMIAMI SYLV)



Patient Contact Form



- Please include time zone
- Submit within 24hours of registration in OPEN
- Email with encryption to symon@miami.edu
 - If encryption not an option, contact symon@miami.edu for alternative method

Consent Date:
Site ID:
Patient ID: CC012CD
Patient Name
Patient Address
Patient Preferred Language (select one): English 🗌 Spanish 🗌
Patient Phone Number Cell 📃 Landline
Patient Alternate Phone Number Cell 🗌 Landline 🗌
Preferred Days and Times for Interviews: Day of the week Time (loca, include time zone)
Preferred Days and Times for IVR Calls: Day of the week Time (local include time zone)
Instructions: 1. Complete within 24 hours of patient registration in OPEN

NRG-CC012CD "SYMON"


Patient Contact Information Form

2. When complete, email with encryption security to symon@miami.edu






Practice Personnel Activities







What happens between patient enrollment and beginning to receive IVR reports each week for your patients?







Example Weekly IVR Report

- Will be sent within ~24hrs of symptom monitoring telephone call, after each weekly call
- Can be sent to as many people as preferred

Record ID CC012CD-00001

Provider Report

Patient Name: Elle Example MRN: 1234567 Study Start Date: 06/28/2024 Below is a summary of your patient's symptoms reported on <u>06/29/2024</u>

Severe Symptoms

Cough: 4 Arm or leg swelling: 3 Pain: 4 Vomiting: 4

Moderate Symptoms

Pounding or racing heartbeat (Palpitations): 2 Hand-foot syndrome: 2 Headache: 1


No Symptoms Reported

Shortness of breath: 0 Tingling in Hands or Feet: 0 Dizziness: 0 Problems with concentration: 0 Insomnia: 0 Fatique: 0 Anxiety: 0 Feeling that nothing could cheer you up: 0 Sad or unhappy feelings: 0 Shivering or shaking chills: 0 Unexpected or excessive sweating: 0 Dry mouth: 0 Mouth or throat sores: 0 Decreased appetite: 0 Nausea: 0 Constipation: 0 Diarrhea: 9 (Refused to answer)





Data Management





Learn More

- Contact us!
 - Jamillah Gross-Caldwell & Grey Freylersythe SYMON@miami.edu
- Resources
 - General information:
 - www.craneresearchlab.org/cc012cd
 - Monthly Update slides will be posted here after each monthly meeting
 - www.nrgoncology.org/Clinical-Trials/Protocol/nrg--cc012cd?filter=nrg--cc012cd
 - NRG Meeting Kick-Off Training
 - nrg2024winter.s3.amazonaws.com/RG-CC012CD+Workshop.mp4







Questions?



MICHIGAN STATE



